Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Huntington's chorea-- measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.

Literature DB >> 6167683

Huntington's chorea-- measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.

H Cramer, J Kohler, G Oepen, G Schomburg, E Schröter.

Abstract

Somatostatin, substance P, cyclic AMP and cyclic GMP were determined in the cerebrospinal fluid of patients with Huntington's disease, in first generation relatives of choreic patients and in neurological control patients. Substance P levels were not significantly altered, but somatostatin levels were markedly decreased both in affected patients and symptom-free offspring. Cyclic AMP was decreased only in patients with advanced stages of the disease while cyclic GMP was normal. Evidence is discussed which may support a role of somatostatin deficiency in the pathophysiology of chorea.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1981 PMID： 6167683 DOI： 10.1007/BF00313747

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

19 in total

1. Radioimmunoassay for GH-release inhibiting hormone.

Authors: A Arimura; H Sato; D H Coy; A V Schally
Journal: Proc Soc Exp Biol Med Date: 1975-03

2. Guanosine 3', 5'-cyclicmonophosphate assay at 10(-15)-mole level.

Authors: H L Cailla; C J Vannier; M A Delaage
Journal: Anal Biochem Date: 1976-01 Impact factor: 3.365

3. Cyclic amp concentration and enzyme activities of cerebrospinal fluid in patients with epilepsy or central nervous system damage.

Authors: V V Myllylä; E R Heikkinen; H Vapaatalo; E Hokkanen
Journal: Eur Neurol Date: 1975 Impact factor: 1.710

4. Localization in and release of somatostatin from brain and gut.

Authors: B L Pimstone; M Sheppard; B Shapiro; S Kronheim; A Hudson; S Hendricks; K Waligora
Journal: Fed Proc Date: 1979-08

5. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors: J W Kebabian; G L Petzold; P Greengard
Journal: Proc Natl Acad Sci U S A Date: 1972-08 Impact factor: 11.205

6. Immunoreactive somatostatin release from rat spinal cord in vitro.

Authors: M Sheppard; S Kronheim; C Adams; B Pimstone
Journal: Neurosci Lett Date: 1979-11 Impact factor: 3.046

7. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus.

Authors: T Hökfelt; S Efendić; C Hellerström; O Johansson; R Luft; A Arimura
Journal: Acta Endocrinol Suppl (Copenh) Date: 1975

8. Somatostatin in human cerebrospinal fluid.

Authors: Y Patel; K Rao; S Reichlin
Journal: N Engl J Med Date: 1977-03-10 Impact factor: 91.245

9. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

Authors: E G Spokes
Journal: Brain Date: 1980-03 Impact factor: 13.501

10. Disturbance of eye movements in Huntington's chorea.

Authors: G Oepen; P Clarenbach; U Thoden
Journal: Arch Psychiatr Nervenkr (1970) Date: 1981

10 in total

Review 1. Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors: A Leake; I N Ferrier
Journal: Drugs Aging Date: 1993 Sep-Oct Impact factor: 3.923

Review 2. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors: Antonella Cardinale; Francesca R Fusco
Journal: CNS Neurosci Ther Date: 2018-03-03 Impact factor: 5.243

3. Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus.

Authors: M A Poca; M Mataró; J Sahuquillo; R Catalán; J Ibañez; R Galard
Journal: J Neurol Neurosurg Psychiatry Date: 2001-03 Impact factor: 10.154

Huntington's chorea-- measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.

1. Radioimmunoassay for GH-release inhibiting hormone.

2. Guanosine 3', 5'-cyclicmonophosphate assay at 10(-15)-mole level.

3. Cyclic amp concentration and enzyme activities of cerebrospinal fluid in patients with epilepsy or central nervous system damage.

4. Localization in and release of somatostatin from brain and gut.

5. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

6. Immunoreactive somatostatin release from rat spinal cord in vitro.

7. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus.

8. Somatostatin in human cerebrospinal fluid.

9. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

10. Disturbance of eye movements in Huntington's chorea.

Review 1. Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Review 2. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

3. Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus.

4. Somatostatin cerebrospinal fluid levels in dementia.

5. Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.

6. Huntington's disease - imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk.

7. Somatostatin-like immunoreactivity in the cerebrospinal fluid of neurological patients.

8. Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.

Review 9. Neuropeptides in dopamine-containing regions of the brain.

10. Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.